Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice

Journal of Clinical Investigation

Volumn 104, Issue 4, 1999, Pages 375-381

  Barton Davis, Elisabeth R ^a   Cordier, Laurence ^a   Shoturma, Daria I ^a   Leland, Stuart E ^a   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; DYSTROPHIN; GENTAMICIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKELETAL MUSCLE; STOP CODON;

EID: 0032720705     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7866     Document Type: Article

References (29)

1. Moser, H. 1984. Duchenne muscular dystrophy: pathogenic aspects and genetic prevention. Hum. Genet. 66:17-40.
2. Koenig, M., Monaco, A.P., and Kunkel, L.M. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:219-228.
3. Koenig, M., et al. 1987. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 50:509-517.
4. Hoffman, E.P. 1991. Molecular diagnostics of Duchenne/Becker dystrophy: new additions to a rapidly expanding literature. J. Neurol. Sci. 101:129-132.
5. Prior, T. W., et al. 1995. Spectrum of small mutations in the dystrophin coding region. Am. J. Hum. Genet. 57:22-33.
6. Sicinski, P. et al. 1989. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1578-1580.
7. Karpati, G., Carpenter, S., and Prescott, S. 1988. Small-caliber skeletal fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve. 11:795-803.
8. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M., and Sweeney, H.L. 1993. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA. 90:3710-3714.
9. Stedman, H.H., et al. 1991. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 352:536-539.
10. Palmer, E., Wilhelm, J.M., and Sherman, F. 1979. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature. 277:148-150.
11. Singh, A., Ursic, D.,and Davies, J. 1979. Phenotypic suppression and misreading in Saccharomyces cerevisiae. Nature. 277:146-148.
12. Bedwell, D.M., et al. 1997. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 3:1280-1284.
13. Howard, M., Frizzell, R.A., and Bedwell, D.M. 1996. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop codons. Nat. Med. 2:467-469.
14. Neville, C., Rosenthal, N., McGrew, M., Bogdanova, N., and Hauschka, S. 1998. Skeletal muscle cultures. In Methods in all biology. Volume 52. H.L. Sweeney and C. Emerson, editors. Academic Press. San Diego, CA. 85-116.
15. Sweeney, H.L., and Feng, H. 1998. Structure-function analysis of cytoskeletal/contractile proteins in avian myotubes. In Methods in cell biology. Volume 52. H.L. Sweeney and C. Emerson, editors. Academic Press. San Diego, CA. 275-282.
16. Morris, T.H. 1995. Antibiotic therapeutics in laboratory animals. Lab. Anim. 29:16-36.
17. Swan, S.K. 1997. Aminoglycoside nephrotoxicity. Semin. Nepbrol. 17:27-33.
18. Barton-Davis, E.R., Shoturma, D.I., Musaro, A., Rosenthal, N., and Sweeney, H.L. 1998. Viral-mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl. Acad. Sci. USA. 95:15603-15607.
19. Ervasti, J.M., and Campbell, K.P. 1991. Membrane organization of the dystrophin-glycoprotein complex. Cell. 66:1121-1131.
20. Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:919-928.
21. McNally, E.M., et al. 1996. Mutations that disrupt the carboxyl-terminus of γ-sarcoglycan cause muscular dystrophy. Hum. Mol. Genet. 5:1841-1847.
22. Rafael, J.A., et al. 1994. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum. Mol. Genet. 3:1725-1733.
23. Song, B., and Schacht, J. 1996. Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hear. Res. 94:87-93.
24. Pearce, R.A., Finley, R.J., Mustard, R.A., and Duff, J.H. 1985. 2,3-dihydroxybenzoic acid. Arch. Surg. 120:937-940.
25. Hauser, M.A., and Chamberlain, J.S. 1996. Progress towards gene therapy for Duchenne muscular dystrophy. J. Endocrinol. 149:373-378.
26. Karpati, G., and Ascadi, G. 1993. The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. Muscle Nerve. 16:1141-1153.
27. Hauser, M.A., Amalfitano, A., Kumar-Singh, R., Hauschka, S.D., and Chamberlain, J.S. 1997. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul. Disord. 7:277-283.
28. Phelps, S.F., et al. 1995. Expression of full-length and truncated dystrophin mini-genes in transgeinc mdx mice. Hum. Mol. Genet. 4:1251-1258.
29. Tuffery, S. et al. 1998. Mutation analysis of the dystrophin gene in Southern French DMD or BMD families: from Southern blot to protein truncation test. Hum. Genet. 102:334-342.